Biogen: LEQEMBI Real-World LEADER Study Shows Majority Of Early Alzheimer's Patients Remain Stable

Biogen and Eisai presented real-world LEADER study results at AAIC 2026 showing ~83% of early Alzheimer’s patients on LEQEMBI were stable (75.9%) or improved (6.6%) over an average of 17 months. The outcome is supportive of LEQEMBI’s real-world effectiveness and is likely to be viewed positively by the market, though it appears incremental rather than company-wide transformative.

Analysis

Biogen and Eisai presented real-world LEADER study results at AAIC 2026 showing ~83% of early Alzheimer’s patients on LEQEMBI were stable (75.9%) or improved (6.6%) over an average of 17 months. The outcome is supportive of LEQEMBI’s real-world effectiveness and is likely to be viewed positively by the market, though it appears incremental rather than company-wide transformative.